Targeted Genetics issued patent for AAV vector manufacturing processes

By Lisa Kerner

Erie, Pa., Feb. 10 - Targeted Genetics Corp. said it has been issued an additional patent related to its adeno-associated virus (AAV) vector manufacturing processes, U.S. Patent No. 6,995,006.

The patent describes an AAV manufacturing process in which growth conditions, used to culture cell production, are controlled in a manner that leads to the release of AAV vector particles into the cell culture medium without the need for breaking open the host cell membrane, according to a company news release.

This release of vector particles allows for vector harvesting procedures that are scalable to meet commercial needs, and eliminates contaminants that may occur with other vector harvest methods, officials said. The result is improved production quality and a more cost-effective approach to large-scale manufacturing of AAV vectors.

AAV vectors are the vector of choice for developing gene-transfer treatments for a wide variety of chronic disease and the development of viral vaccines, the company said.

Targeted Genetics is a Seattle-based biotechnology company that develops and commercializes targeted molecular therapies for the treatment of inflammatory arthritis, HIV/AIDS and other acquired and inherited diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.